BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public

There’s been no festive respite for Bristol Myers Squibb’s M&A team as the Big Pharma follows up its acquisition of Karuna Therapeutics with the announcement straight after Christmas that it's also buying radiopharmaceuticals-focused RayzeBio for cash.